These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35765279)

  • 1. Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma.
    Teshima T; Kobayashi Y; Kawai T; Kushihara Y; Nagaoka K; Miyakawa J; Akiyama Y; Yamada Y; Sato Y; Yamada D; Tanaka N; Tsunoda T; Kume H; Kakimi K
    Oncol Lett; 2022 Aug; 24(2):265. PubMed ID: 35765279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
    Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
    Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senescent phenotypes and telomere lengths of peripheral blood T-cells mobilized by acute exercise in humans.
    Simpson RJ; Cosgrove C; Chee MM; McFarlin BK; Bartlett DB; Spielmann G; O'Connor DP; Pircher H; Shiels PG
    Exerc Immunol Rev; 2010; 16():40-55. PubMed ID: 20839490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy.
    Kim KH; Pyo H; Lee H; Oh D; Noh JM; Ahn YC; Yoon HI; Moon H; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ku BM; Ahn MJ; Shin EC
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):415-425. PubMed ID: 35150786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
    Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients.
    Shirasuna K; Ito M; Matsuda T; Enomoto T; Ohara Y; Yamamoto M; Nishijima S; Ohkohchi N; Kuromitsu S
    PLoS One; 2020; 15(12):e0243643. PubMed ID: 33370317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
    Sumiyoshi I; Okabe T; Togo S; Takagi H; Motomura H; Ochi Y; Shimada N; Haraguchi M; Shibayama R; Fujimoto Y; Watanabe J; Iwai M; Kadoya K; Iwakami SI; Takahashi K
    J Transl Med; 2021 Feb; 19(1):92. PubMed ID: 33639962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
    Liao JB; Gwin WR; Urban RR; Hitchcock-Bernhardt KM; Coveler AL; Higgins DM; Childs JS; Shakalia HN; Swensen RE; Stanton SE; Tinker AV; Wahl TA; Ancheta RG; McGonigle KF; Dai JY; Disis ML; Goff BA
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience.
    Crist M; Iyer G; Hsu M; Huang WC; Balar AV
    Ther Adv Urol; 2019; 11():1756287219839285. PubMed ID: 31057668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
    Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
    Zhang T; Harrison MR; O'Donnell PH; Alva AS; Hahn NM; Appleman LJ; Cetnar J; Burke JM; Fleming MT; Milowsky MI; Mortazavi A; Shore N; Sonpavde GP; Schmidt EV; Bitman B; Munugalavadla V; Izumi R; Patel P; Staats J; Chan C; Weinhold KJ; George DJ
    Cancer; 2020 Oct; 126(20):4485-4497. PubMed ID: 32757302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy accelerates immune-senescence and functional impairments of Vδ2
    Bruni E; Cazzetta V; Donadon M; Cimino M; Torzilli G; Spata G; Leonardi G; Dieli F; Mikulak J; Mavilio D
    J Immunother Cancer; 2019 Dec; 7(1):347. PubMed ID: 31829255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exhaustion and senescence of CD4 and CD8 T cells that express co-stimulatory molecules CD27 and CD28 in subjects that acquired HIV by drug use or by sexual route.
    Bănică L; Vlaicu O; Jipa R; Abagiu A; Nicolae I; Neaga E; Oţelea D; Paraschiv S
    Germs; 2021 Mar; 11(1):66-77. PubMed ID: 33898343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
    J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.